Prognostic and clinicopathologic significance of long non-coding RNA opa-interacting protein 5-antisense RNA 1 in multiple human cancers

References

• Fitzmaurice C, Akinyemiju TF, et al., Global Burden of Disease Cancer. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–1568.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Thun MJ, DeLancey JO, Center MM, Jemal A, et al. The global burden of cancer: priorities for prevention. Carcinogenesis 2010;31(1):100–110.
   PubMed Web of Science ®Google Scholar
• Karanikas M, Esempidis A, Chasan ZT, et al. Pancreatic cancer from molecular pathways to treatment opinion. J Cancer 2016;7(10):1328–1339.
   PubMed Web of Science ®Google Scholar
• Deng J, Deng H, Liu C, et al. Long non-coding RNA OIP5-AS1 functions as an oncogene in lung adenocarcinoma through targeting miR-448/Bcl-2. Biomed Pharmacother. 2018;98:102–110.
   PubMed Web of Science ®Google Scholar
• Lu H, Liu H, Yang X, et al. LncRNA BLACAT1 may serve as a prognostic predictor in cancer: evidence from a meta-analysis. Biomed Res Int. 2019;2019:1–10.
   Web of Science ®Google Scholar
• He J, Tu C, Liu Y. Role of lncRNAs in aging and age-related diseases. Aging Med. 2018;1(2):158–175.
   PubMedGoogle Scholar
• He A, He S, Li X, et al. ZFAS1: a novel vital oncogenic lncRNA in multiple human cancers. Cell Prolif. 2019;52(1):e12513.
   PubMed Web of Science ®Google Scholar
• Yan X, Zhu Y, Li F, et al. The value of long noncoding RNA CASC2 as a biomarker of prognosis in carcinomas: a meta-analysis. J Cancer 2018;9(21):3824–3830.
   PubMed Web of Science ®Google Scholar
• Wu Y, Ding M, Wei S, et al. The prognostic value of long noncoding RNA ZEB1-AS1 on clinical outcomes in human cancer. J Cancer 2018;9(20):3690–3698.
   PubMed Web of Science ®Google Scholar
• Mao H, Wang K, Feng Y, et al. Prognostic role of long non-coding RNA XIST expression in patients with solid tumors: a meta-analysis. Cancer Cell Int. 2018;18(1):34.
   PubMedGoogle Scholar
• Mu S, Ai L, Fan F, et al. Prognostic and clinicopathological significance of long noncoding RNA HOXA11-AS expression in human solid tumors: a meta-analysis. Cancer Cell Int. 2018;18:1.
   PubMed Web of Science ®Google Scholar
• Li J, Cui Z, Li H, et al. Clinicopathological and prognostic significance of long noncoding RNA MALAT1 in human cancers: a review and meta-analysis. Cancer Cell Int. 2018;18(1):109.
   PubMedGoogle Scholar
• Zhang H, Zhu M, Du Y, et al. A panel of 12-lncRNA signature predicts survival of pancreatic adenocarcinoma. J Cancer 2019;10(6):1550–1559.
   PubMed Web of Science ®Google Scholar
• Chen C, Feng Y, Wang X. LncRNA ZEB1-AS1 expression in cancer prognosis: review and meta-analysis. Clin Chim Acta 2018;484:265–271.
   PubMed Web of Science ®Google Scholar
• Liang J, Wei X, Liu Z, et al. Long noncoding RNA CYTOR in cancer: a TCGA data review. Clin Chim Acta 2018;483:227–233.
   PubMed Web of Science ®Google Scholar
• Kim J, Abdelmohsen K, Yang X, et al. LncRNA OIP5-AS1/cyrano sponges RNA-binding protein HuR. Nucleic Acids Res. 2016;44(5):2378–2392.
   PubMed Web of Science ®Google Scholar
• Lennox KA, Behlke MA. Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res. 2016;44(2):863–877.
   PubMed Web of Science ®Google Scholar
• Kim J, Noh JH, Lee SK, et al. LncRNA OIP5-AS1/cyrano suppresses GAK expression to control mitosis. Oncotarget 2017;8(30):49409–49420.
   PubMedGoogle Scholar
• Arunkumar G, Anand S, Raksha P, et al. LncRNA OIP5-AS1 is overexpressed in undifferentiated oral tumors and integrated analysis identifies as a downstream effector of stemness-associated transcription factors. Sci Rep. 2018;8(1):7018.
   PubMedGoogle Scholar
• Zhang Z, Liu F, Yang F, et al. Kockdown of OIP5-AS1 expression inhibits proliferation, metastasis and EMT progress in hepatoblastoma cells through up-regulating miR-186a-5p and down-regulating ZEB1. Biomed Pharmacother. 2018;101:14–23.
   PubMed Web of Science ®Google Scholar
• Naemura M, Kuroki M, Tsunoda T, et al. The long noncoding RNA OIP5-AS1 is involved in the regulation of cell proliferation. Anticancer Res. 2018;38(1):77–81.
   PubMed Web of Science ®Google Scholar
• Yang N, Chen J, Zhang H, et al. LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma. Cell Death Dis. 2017;8(8):e2975–e2975.
   PubMedGoogle Scholar
• Zou Y, Yao S, Chen X, et al. LncRNA OIP5-AS1 regulates radioresistance by targeting DYRK1A through miR-369-3p in colorectal cancer cells. Eur J Cell Biol. 2018;97(5):369–378.
   PubMed Web of Science ®Google Scholar
• Kun-Peng Z, Chun-Lin Z, Xiao-Long M, et al. Fibronectin-1 modulated by the long noncoding RNA OIP5-AS1/miR-200b-3p axis contributes to doxorubicin resistance of osteosarcoma cells. J Cell Physiol. 2019;234(5):6927–6939.
   PubMed Web of Science ®Google Scholar
• Song L, Zhou Z, Gan Y, et al. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. J Cell Biochem. 2019;120(6):9656–9666.
   PubMed Web of Science ®Google Scholar
• Dai J, Xu L, Hu X, et al. Long noncoding RNA OIP5-AS1 accelerates CDK14 expression to promote osteosarcoma tumorigenesis via targeting miR-223. Biomed Pharmacother. 2018;106:1441–1447.
   PubMed Web of Science ®Google Scholar
• Wang M, Sun X, Yang Y, et al. Long non-coding RNA OIP5-AS1 promotes proliferation of lung cancer cells and leads to poor prognosis by targeting miR-378a-3p. Thorac Cancer 2018;9(8):939–949.
   PubMed Web of Science ®Google Scholar
• Wang Y, Shi F, Xia Y, et al. LncRNA OIP5-AS1 predicts poor prognosis and regulates cell proliferation and apoptosis in bladder cancer. J Cell Biochem. 2018;120:7499–7505.
   PubMed Web of Science ®Google Scholar
• Yang J, Jiang B, Hai J, et al. Long noncoding RNA opa-interacting protein 5 antisense transcript 1 promotes proliferation and invasion through elevating integrin α6 expression by sponging miR-143-3p in cervical cancer. J Cell Biochem. 2019;120(1):907–916.
   PubMed Web of Science ®Google Scholar
• Zeng H, Wang J, Chen T, et al. Downregulation of long non-coding RNA Opa interacting protein 5-antisense RNA 1 inhibits breast cancer progression by targeting sex-determining region Y-box 2 by microRNA-129-5p upregulation. Cancer Sci. 2019;110(1):289–302.
   PubMed Web of Science ®Google Scholar
• Sun WL, Kang T, Wang YY, et al. Long noncoding RNA OIP5-AS1 targets Wnt-7b to affect glioma progression via modulation of miR-410. Biosci Rep. 2019;39(1):BSR20180395.
   PubMedGoogle Scholar
• Liu X, Zheng J, Xue Y, et al. PIWIL3/OIP5-AS1/miR-367-3p/CEBPA feedback loop regulates the biological behavior of glioma cells. Theranostics 2018;8(4):1084–1105.
   PubMed Web of Science ®Google Scholar
• Luan W, Zhang X, Ruan H, et al. Long noncoding RNA OIP5-AS1 acts as a competing endogenous RNA to promote glutamine catabolism and malignant melanoma growth by sponging miR-217. J Cell Physiol. 2019;234(9):16609–16618.
   PubMed Web of Science ®Google Scholar
• Esfandi F, Kholghi Oskooei V, Taheri F, et al. Expression analysis of OIP5-AS1 in non-small cell lung cancer. Klin Onkol. 2018;31(4):260–263.
   PubMedGoogle Scholar
• Chiu H-S, Somvanshi S, Patel E, et al. Pan-cancer analysis of lncRNA regulation supports their targeting of cancer genes in each tumor context. Cell Rep. 2018;23(1):297–312.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339(1):b2700–b2700.
   PubMed Web of Science ®Google Scholar
• Xu L, Yan NN, Li ZH, et al. A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis. OTT. 2018;11:8389–8398.
   Google Scholar
• Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(1):556–560.
   Google Scholar
• Tan J, Hou YC, Fu LN, et al. Long noncoding RNA CCAT2 as a potential novel biomarker to predict the clinical outcome of cancer patients: a meta-analysis. J Cancer 2017;8(8):1498–1506.
   PubMed Web of Science ®Google Scholar
• Wang X, Kan J, Han J, et al. LncRNA SNHG16 functions as an oncogene by sponging MiR-135a and promotes JAK2/STAT3 signal pathway in gastric cancer. J Cancer 2019;10(4):1013–1022.
   PubMed Web of Science ®Google Scholar
• Zhang X, Mao L, Li L, et al. Long noncoding RNA GIHCG functions as an oncogene and serves as a serum diagnostic biomarker for cervical cancer. J Cancer 2019;10(3):672–681.
   PubMed Web of Science ®Google Scholar
• Liao D, Lv G, Wang T, et al. Prognostic value of long non-coding RNA BLACAT1 in patients with papillary thyroid carcinoma. Cancer Cell Int. 2018;18(1):47.
   PubMed Web of Science ®Google Scholar
• Tan BS, Yang MC, Singh S, et al. LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. Oncogene 2019;38(28):5612–5626.
   PubMed Web of Science ®Google Scholar
• Ju W, Luo X, Zhang N. LncRNA NEF inhibits migration and invasion of HPV-negative cervical squamous cell carcinoma by inhibiting TGF-β pathway. Biosci Rep. 2019;39(4):BSR20180878.
   PubMedGoogle Scholar
• Chen X, Xiong D, Yang H, et al. Long noncoding RNA OPA-interacting protein 5 antisense transcript 1 upregulated SMAD3 expression to contribute to metastasis of cervical cancer by sponging miR-143-3p. J Cell Physiol. 2019;234(4):5264–5275.
   PubMed Web of Science ®Google Scholar